Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.

Franco R, Rodriguez JM, Elías F, Hernando-Insúa A, Fló J, López R, Nagle C, Lago N, Zorzopulos J, Horn DL, Montaner AD.

Nucleic Acid Ther. 2014 Aug;24(4):267-82. doi: 10.1089/nat.2013.0479. Epub 2014 Apr 10.

2.

A safety study of a B-class CpG ODN in Sprague-Dawley rats.

Liu L, Shen L, Liu X, Yu Y, Li Y, Wang L, He C, Sun J, Li B.

J Appl Toxicol. 2012 Jan;32(1):60-71. doi: 10.1002/jat.1683. Epub 2011 Apr 29.

PMID:
21538408
3.

Oligodeoxynucleotide IMT504: lack of effect on immune parameters during islet regeneration in single dose streptozotocin-induced diabetes.

Bianchi MS, Calvo V, Chasseing NA, Lago N, Libertun C, Montaner AD, Lux-Lantos VA.

Diabetes Metab Res Rev. 2012 Feb;28(2):156-63. doi: 10.1002/dmrr.1296.

PMID:
21922635
4.
5.

NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).

National Toxicology Program .

Natl Toxicol Program Tech Rep Ser. 1993 Sep;422:1-340.

6.

Oligonucleotide IMT504 reduces neuropathic pain after peripheral nerve injury.

Coronel MF, Hernando-Insúa A, Rodriguez JM, Elias F, Chasseing NA, Montaner AD, Villar MJ.

Neurosci Lett. 2008 Oct 17;444(1):69-73. doi: 10.1016/j.neulet.2008.07.045. Epub 2008 Jul 23.

PMID:
18672022
7.

PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant hepatitis B vaccine that enhances the Th1 response.

Elias F, Flo J, Rodriguez JM, De Nichilo A, Lopez RA, Zorzopulos J, Nagle C, Lahoz M, Montaner A.

Vaccine. 2005 May 20;23(27):3597-603.

PMID:
15855019
8.

The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Chahin A, Opal SM, Zorzopulos J, Jobes DV, Migdady Y, Yamamoto M, Parejo N, Palardy JE, Horn DL.

Antimicrob Agents Chemother. 2015 Feb;59(2):1225-9. doi: 10.1128/AAC.03923-14. Epub 2014 Dec 15.

10.

Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.

Monteith DK, Geary RS, Leeds JM, Johnston J, Monia BP, Levin AA.

Toxicol Sci. 1998 Dec;46(2):365-75.

PMID:
10048140
11.

Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.

Wilson KD, Raney SG, Sekirov L, Chikh G, deJong SD, Cullis PR, Tam YK.

Int Immunopharmacol. 2007 Aug;7(8):1064-75. Epub 2007 May 2.

PMID:
17570323
13.

Acute, subchronic and chronic safety studies with genistein in rats.

Michael McClain R, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J.

Food Chem Toxicol. 2006 Jan;44(1):56-80. Epub 2005 Oct 6.

PMID:
16213646
14.
16.
18.

Twenty-eight days repeated oral dose toxicity study of gemifloxacin in Wistar albino rats.

Roy B, Sarkar AK, Sengupta P, Dey G, Das A, Pal TK.

Regul Toxicol Pharmacol. 2010 Nov;58(2):196-207. doi: 10.1016/j.yrtph.2010.05.008. Epub 2010 May 23.

PMID:
20580917
19.
20.

Supplemental Content

Support Center